Clinical trial Recruiting at 1 site Observational

UllCORE BSI Test for Bloodstream Infections

Official title: Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test

Run by Deepull Diagnostics S.L. · NCT07859852 · Data updated 2026-11-12

This study tests whether the UllCORE BSI Test can correctly detect bloodstream infection pathogens and resistance markers from whole blood in people with suspected infection or sepsis.

Quick facts

Study typeObservational
SexAll
Enrollment1500 (estimated)
SponsorDeepull Diagnostics S.L.
Industry-sponsored
Locations20 sites (Orange, California and 19 other locations)
StatusRecruiting
StartedSeptember 21, 2026
Main results expectedApril 2027
Study endsOctober 2027
Registry record updatedOctober 8, 2026
Trial IDNCT07859852 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults and children with signs of suspected bloodstream infection or sepsis who can provide consent and have two EDTA blood tubes collected alongside standard-of-care cultures.

Probably not a fit

Patients whose bloodstream infection is not detectable by the UllCORE BSI Test or whose infection does not require detection of the tested resistance markers may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study compares the UllCORE BSI Test results from whole blood with standard blood culture results in patients with suspected bloodstream infection or sepsis. Samples are collected at the same time as routine blood cultures and tested either fresh or after freezing, following a predefined protocol. The goal is to characterize the diagnostic performance of the investigational test without using its results to guide patient care. Data from multiple sites, including UC Irvine Medical Center, Tampa General Hospital, and Johns Hopkins Hospital, will support sensitivity, specificity, and concordance analyses against conventional microbiology methods. No clinical decisions will be made based on UllCORE BSI Test results for this study.

Why it matters

Potential benefit: If successful, the UllCORE BSI Test could improve rapid detection of bloodstream pathogens and resistance markers, potentially informing future patient care.

How similar studies have gone: Prior work in molecular diagnostics for bloodstream infections has shown promise, but this exact test in whole-blood samples is relatively novel and its clinical utility is still being established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Any age (where the remaining criteria can be safely fulfilled)
* Ability to provide consent/assent in accordance with Institutional Review Board (IRB)/Ethics Committee (EC) determinations
* The patient is presenting with signs and symptoms of suspected bloodstream infection (BSI) or fulfils the criteria for the hospital sepsis protocol.

Planned blood culture collection and laboratory analysis as per standard of care (SOC).

• Patient is able and an appropriate candidate to be able to collect 2 K2 ethylenediaminetetraacetic acid (EDTA) tubes of whole blood.

Exclusion Criteria:

* Unable to collect UllCORE BSI Test samples from the same venipuncture as blood culture (BC) samples
* Patient was previously enrolled in the study

Where it's running

  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio, United States
    Recruiting
  • University of California at Irvine Medical Center
    Orange, California, United States
    Not yet recruiting
  • Tampa General Hospital
    Tampa, Florida, United States
    Not yet recruiting
  • The Johns Hopkins Hospital
    Baltimore, Maryland, United States
    Not yet recruiting
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts, United States
    Not yet recruiting
  • Henry Ford Health
    Novi, Michigan, United States
    Not yet recruiting
Show 14 more locations
  • Washington University School of Medicine
    St Louis, Missouri, United States
    Not yet recruiting
  • Geisinger Health
    Danville, Pennsylvania, United States
    Not yet recruiting
  • Vanderbilt health
    Nashville, Tennessee, United States
    Not yet recruiting
  • Baylor Scott & White Health Medical Center-Temple
    Temple, Texas, United States
    Not yet recruiting
  • CHU de Limoges - Hôpital Dupuytren
    Limoges, France
    Not yet recruiting
  • Hôpital de la Croix-Rousse - HCL
    Lyon, France
    Not yet recruiting
  • Charité - Campus Benjamin Franklin
    Berlin-Zehlendorf, Germany
    Not yet recruiting
  • Universitaetsklinikum Jena
    Jena, Germany
    Not yet recruiting
  • Universitaetsklinikum Leipzig
    Leipzig, Germany
    Not yet recruiting
  • Azienda Ospedaliera Universitaria Careggi
    Florence, Italy
    Not yet recruiting
  • Ospedale di Perugia Santa Maria della Misericordia
    Perugia, Italy
    Not yet recruiting
  • Hospital Germans Trias I Pujol
    Badalona, Spain
    Not yet recruiting
  • Hospital Universitari Vall d'Hebron - VHIO
    Barcelona, Spain
    Not yet recruiting
  • Hospital Clínic de Barcelona
    Barcelona, Spain
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • New care guideline for infants 60 days and younger with fever in Sweden

    This project will test a new guideline to see if infants 60 days or younger with fever can safely avoid many invasive tests, hospital stays, and broad antibiotics compared with usual care.

    Recruiting at 9 sites Region Skane · Gothenburg and 10 other locations · NCT07134751

  • Improving vancomycin dosing for young infants with infections

    This study is testing a new way to give the right amount of vancomycin to young infants with infections to help them get better faster.

    Recruiting at 2 sites Phase 4 Murdoch Childrens Research Institute · Melbourne, Victoria and 3 other locations · NCT05770622

  • Using fosfomycin to treat severely infected patients

    This study is testing if an intravenous antibiotic called fosfomycin can safely help people with serious infections like osteomyelitis and bacterial meningitis feel better.

    Recruiting at 45 sites Infectopharm Arzneimittel GmbH · Hall in Tirol and 49 other locations · NCT02979951

  • Pneumococcal infection surveillance in Lebanon

    This study is trying to find out which types of bacteria cause serious infections like pneumonia in Lebanon and how well current vaccines and antibiotics work against them.

    Recruiting American University of Beirut Medical Center · Beirut · NCT00901602

  • Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care

    This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.

    Recruiting Ain Shams University · Cairo, Cairo Governorate · NCT07922213

  • Early detection of sepsis-related blood clotting problems in severe burn patients

    This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.

    Recruiting Center for Traumatology and Major Burns, Ben Arous · Tunis · NCT07914205

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.